| Literature DB >> 30705253 |
Christopher L Wright1, Jessica H Hoffman1, Margaret M McCarthy2.
Abstract
Discovering and characterizing critical and sensitive periods in brain development is essential for unraveling the myriad variables that impact disease risk. In previous work, we identified a critical period in cerebellar development in the rat that depends upon an intrinsic gene expression program and links increased prostaglandin production to local estradiol synthesis by stimulating Cyp19a, the estradiol synthetic enzyme, aromatase. This intrinsic critical period is sensitive to disruption by either inflammation or administration of cyclooxygenase (COX) inhibitors, ultimately impacting Purkinje cell dendritic growth. In a first step towards determining if a similar sensitive period exists in humans, the same gene expression profile was characterized in post-mortem cerebellar tissue of 58 children aged 0 to 9 years. Subjects were categorized as experiencing inflammation or not at the time of death. In individuals experiencing inflammation and over 1 year of age, there was a significant increase in the messenger RNA (mRNA) of the COX-1 and COX-2 enzymes and this strongly correlated with mRNA levels of aromatase. A step-wise linear model accounted for 94% of the variance in aromatase mRNA levels by co-variance with the COX enzymes, prostaglandin E2 synthase and other inflammatory mediators (Toll-like receptor 4), and Purkinje cell markers (calbindin, estrogen receptor 2). The influence of inflammation on these measures was not seen in subjects younger than 1 year. These data suggest a sensitive period to inflammation in the human cerebellum begins at about 1 year of age and may provide insight into sources of vulnerability of very young children to either inflammation or drugs designed to treat it.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30705253 PMCID: PMC6355799 DOI: 10.1038/s41398-018-0363-8
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Demographics and covariates of human samples
| Variable | Less than 365 days old | Greater than 365 days old | ||
|---|---|---|---|---|
| Inflammation | None | Inflammation | None | |
| Age (days) |
|
|
|
|
| PMI |
|
|
|
|
| Sex (F:M) | 4:4 | 6:7 | 9:8 | 5:15 |
| Time tissue remained frozen (days) |
|
|
|
|
| RIN |
|
|
|
|
| pH |
|
|
|
|
| Manner of death | 8 infection | 4 congenital defect, 7 accident, 1 SID, 1 unknown | 6 infection, 3 asphyxia complicated by asthma, 3 asthma attacks, 1 multiple including infection, 1 intussusception of bowel, 1 inflammatory myofibroblastic tumor with T cell infiltrates, 1 cardiac arrest complicated by H1N1 | 17 Accident (MVA or asphyxia), 1 cardiac failure, 1 respiratory failure with multisystem organ failure, 1 congenital defect |
| Medications | Tylenol, Amoxicillin | Cardec | ||
PMI post-mortem interval, MVA motor vehicle accident, RIN RNA integrity number, SID sudden infant death
Fig. 1Gene expression profile of the PGE2-E2 pathway in developing cerebellum.
Subjects were divided into those (a) under 1 year of age and b those older, up to 9 years and categorized as experiencing inflammation or none at the time of death (see text for details and rational). Categorization as inflamed was confirmed by quantification of TLR4 mRNA, which was significantly higher (Finflam = 8.43, *p = 0.005). Levels of mRNA were quantified in cerebellar samples for genes associated with prostaglandin and estradiol synthesis. PTGS1 mRNA was marginally increased in subjects experiencing inflammation regardless of age (Finflam = 6.66, p = 0.077). PTGS1 and CYP19a were significantly increased in inflamed subjects over 1 year of age (PTGS2: Fage × inflam = 6.73, *p = 0.013, CYP19a: Fage ×inflam = 4.36, *p = 0.043). PGE2 prostaglandin E2, TLR4 Toll-like receptor 4, mRNA messenger RNA
Fig. 2Correlations and linear modeling of CYP19a with PGE2 synthesizing enzymes.
a mRNA levels for PTGS1 and b PTGS2 (COX-1 and COX-2, respectively) predict 47 and 42% of the variance in CYP19a mRNA expression after exponential regression of the subjects with inflammation older than 1 year. c When combined into a total PTGS mRNA measure, 57.8% of the variability in CYP19a mRNA was predicted. d PGES1 (PGE synthase) mRNA levels predict 33.5% of the variance in CYP19a mRNA levels in individuals aged 1 to 9 years with inflammation. e Automatic linear modeling confirmed the effects of PGE2 signaling and inflammation on CYP19a—94% of the variance in mRNA expression could be predicted by total PTGS, PGES1, TLR4v4, TLR4v1, CALB1, and ERS2 expression in individuals experiencing inflammation at the time of death. PGE2 prostaglandin E2, COX cyclooxygenase, mRNA messenger RNA
Fig. 3Developmental profile of the PGE2-E2 pathway in cerebellum.
Plotting of individual mRNA levels for each gene across age of subjects reveals that MGLL (*Fage = 43.32, p < 0.001), PGES1 (*Fage = 14.21, p < 0.001), ESR1 (*Fage = 4.63, p = 0.03), and ESR2 (*Fage = 12.21, p < 0.001) changed significantly with age, increasing as individuals got older, with the exception of ESR2 which declined. RNA for other genes measured did not change across development. PGE2 prostaglandin E2, mRNA messenger RNA, ESR2 estrogen receptor 2